Payment overview · 2025
General Payments
$3,273.46
131 reported records · 24 companies
Healthcare provider profile · identity verified
Michael C Wagner, FNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · DANVILLE, IL · NPI 1073655825
Verified facts
What the public records show
CMS Open Payments records show Michael C Wagner, FNP received $3,273.46 in general payments during 2025 across 131 reported records.
AstraZeneca Pharmaceuticals LP accounted for 22.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 35 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Otezla, Ozempic, Rexulti, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Linzess by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Otezla by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 153 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 153 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $739.07 | 22.6% | 27 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $284.96 | 8.7% | 14 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $232.79 | 7.1% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $221.52 | 6.8% | 6 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $189.32 | 5.8% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $162.87 | 5.0% | 9 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $159.55 | 4.9% | 8 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $158.87 | 4.8% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $138.37 | 4.2% | 7 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $135.74 | 4.2% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $134.24 | 4.1% | 4 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $124.59 | 3.8% | 6 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $110.19 | 3.4% | 5 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $101.63 | 3.1% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $85.48 | 2.6% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $80.59 | 2.5% | 5 | 2025 |
| BETA BIONICS, INC. | Unresolved — no canonical attribution shown | $50.16 | 1.5% | 3 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $38.19 | 1.2% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $35.16 | 1.1% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $20.73 | 0.6% | 1 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $20.66 | 0.6% | 1 | 2025 |
| Tandem Diabetes Care, Inc. | Unresolved — no canonical attribution shown | $17.33 | 0.5% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $16.26 | 0.5% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $15.19 | 0.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,273.46 | 131 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $363.02 | 14 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $269.10 | 8 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $256.80 | 12 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $256.80 | 12 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $200.53 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $195.67 | 9 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $189.32 | 8 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $158.87 | 3 | 2025 |
Source payment records
|
|||||
| DEXCOM G7 GSS (161) Normalized: dexcom g7 gss 161 |
Medical Supply | Dexcom, Inc. | $156.20 | 1 | 2025 |
Source payment records
|
|||||
| DEXCOM STELO GLUCOSE BIOSENSOR Normalized: dexcom stelo glucose biosensor |
Not specified | Dexcom, Inc. | $156.20 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $138.79 | 7 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $138.37 | 7 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $135.74 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $134.24 | 4 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $124.59 | 6 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $124.48 | 7 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $101.63 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $80.59 | 5 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $76.59 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $76.05 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $73.98 | 3 | 2025 |
Source payment records
|
|||||
| iLet Bionic Pancreas Normalized: ilet bionic pancreas |
Device | BETA BIONICS, INC. | $50.16 | 3 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Contact Detach Normalized: ilet insulin infusion kit contact detach |
Device | BETA BIONICS, INC. | $50.16 | 3 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Inset Normalized: ilet insulin infusion kit inset |
Device | BETA BIONICS, INC. | $50.16 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $38.39 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $38.19 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $35.16 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $28.16 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $20.76 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $20.73 | 1 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $20.66 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $20.66 | 1 | 2025 |
Source payment records
|
|||||
| t:slim X2 Insulin Pump with Control-IQ Normalized: t slim x2 insulin pump with control iq |
Device | Tandem Diabetes Care, Inc. | $17.33 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $16.26 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $15.19 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 81 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 78 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 153 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 122 | exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 120 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 78 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 83 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
36 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
78 | 15 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
153 | 30 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
81 | 17 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
83 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
153 | 30 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
122 | 25 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
117 | 30 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
78 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
120 | 29 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
78 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Losartan Potassium | Losartan Potassium | 431 | 113 |
| Omeprazole | Omeprazole | 393 | 91 |
| Amlodipine Besylate | Amlodipine Besylate | 294 | 75 |
| Gabapentin | Gabapentin | 281 | 46 |
| Levothyroxine Sodium | Levothyroxine Sodium | 258 | 53 |
| Buspirone Hcl | Buspirone Hcl | 256 | 44 |
| Atorvastatin Calcium | Atorvastatin Calcium | 251 | 68 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 244 | 27 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 227 | 60 |
| Bupropion Hcl Sr | Bupropion Hcl | 226 | 55 |
| Metoprolol Succinate | Metoprolol Succinate | 221 | 51 |
| Entresto | Sacubitril/Valsartan | 210 | 33 |
| Methylprednisolone | Methylprednisolone | 210 | 123 |
| Bupropion Xl | Bupropion Hcl | 209 | 35 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 195 | 58 |
| Chlorthalidone | Chlorthalidone | 178 | 51 |
| Trazodone Hcl | Trazodone Hcl | 162 | 43 |
| Hydrochlorothiazide | Hydrochlorothiazide | 159 | 41 |
| Tramadol Hcl | Tramadol Hcl | 157 | 30 |
| Jardiance | Empagliflozin | 153 | 30 |
| Citalopram Hbr | Citalopram Hydrobromide | 144 | 27 |
| Carvedilol | Carvedilol | 143 | 33 |
| Diclofenac Sodium | Diclofenac Sodium | 133 | 29 |
| Potassium Chloride | Potassium Chloride | 127 | 40 |
| Mounjaro | Tirzepatide | 122 | 25 |
| Ozempic | Semaglutide | 120 | 29 |
| Lisinopril | Lisinopril | 119 | 30 |
| Trulicity | Dulaglutide | 117 | 30 |
| Pregabalin | Pregabalin | 115 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 102 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 97 | 15 |
| Glipizide Er | Glipizide | 91 | 24 |
| Lovastatin | Lovastatin | 91 | 19 |
| Anastrozole | Anastrozole | 88 | 20 |
| Celecoxib | Celecoxib | 88 | 28 |
| Pantoprazole Sodium | Pantoprazole Sodium | 87 | 23 |
| Clonazepam | Clonazepam | 86 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 83 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 83 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 83 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 83 | 16 |
| Aripiprazole | Aripiprazole | 81 | 14 |
| Eliquis | Apixaban | 81 | 17 |
| Levofloxacin | Levofloxacin | 81 | 60 |
| Escitalopram Oxalate | Escitalopram Oxalate | 80 | 21 |
| Farxiga | Dapagliflozin Propanediol | 78 | 15 |
| Rexulti | Brexpiprazole | 78 | 14 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 70 | 18 |
| Allopurinol | Allopurinol | 70 | 16 |
| Meloxicam | Meloxicam | 69 | 23 |
| Metformin Hcl | Metformin Hcl | 69 | 19 |
| Tradjenta | Linagliptin | 65 | 17 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 64 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 62 | 17 |
| Testosterone Cypionate | Testosterone Cypionate | 60 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 59 | 19 |
| Prednisone | Prednisone | 59 | 21 |
| Azithromycin | Azithromycin | 58 | 43 |
| Furosemide | Furosemide | 57 | 21 |
| Montelukast Sodium | Montelukast Sodium | 53 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 52 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 50 | 11 |
| Lorazepam | Lorazepam | 49 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 49 | 33 |
| Nebivolol Hcl | Nebivolol Hcl | 47 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 47 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 46 | 17 |
| Glipizide | Glipizide | 45 | 14 |
| Methocarbamol | Methocarbamol | 45 | 20 |
| Methotrexate | Methotrexate Sodium | 45 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 41 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 41 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 40 | 29 |
| Sildenafil Citrate | Sildenafil Citrate | 40 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 39 | 11 |
| Memantine Hcl | Memantine Hcl | 39 | 12 |
| Donepezil Hcl | Donepezil Hcl | 38 | 11 |
| Sertraline Hcl | Sertraline Hcl | 38 | suppressed |
| Atenolol | Atenolol | 36 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 36 | 12 |
| Fenofibrate | Fenofibrate | 36 | 13 |
| Simvastatin | Simvastatin | 36 | 11 |
| Spironolactone | Spironolactone | 35 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 34 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 34 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 34 | 15 |
| Propranolol Hcl | Propranolol Hcl | 33 | suppressed |
| Dutasteride | Dutasteride | 31 | suppressed |
| Xarelto | Rivaroxaban | 31 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Gemfibrozil | Gemfibrozil | 30 | suppressed |
| Progesterone | Progesterone, Micronized | 30 | 11 |
| Novolog | Insulin Aspart | 29 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 21 |
| Ezetimibe | Ezetimibe | 28 | suppressed |
| Levetiracetam | Levetiracetam | 28 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 27 | 23 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 26 | suppressed |
| Baclofen | Baclofen | 25 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 25 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 24 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 22 | 17 |
| Rybelsus | Semaglutide | 22 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 22 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 22 | suppressed |
| Fluconazole | Fluconazole | 21 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 21 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 21 | 11 |
| Ziprasidone Hcl | Ziprasidone Hcl | 21 | suppressed |
| Clotrimazole | Clotrimazole | 20 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 20 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Omnipod Dash Pods (Gen 4) | Insulin Pump Cart,cont Inf,bt | 19 | suppressed |
| Risperidone | Risperidone | 19 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Torsemide | Torsemide | 18 | suppressed |
| Cephalexin | Cephalexin | 17 | 15 |
| Nortriptyline Hcl | Nortriptyline Hcl | 17 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 17 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 16 | suppressed |
| Metolazone | Metolazone | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Xyosted | Testosterone Enanthate | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 15 | suppressed |
| Klor-Con M20 | Potassium Chloride | 14 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Famotidine | Famotidine | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Finasteride | Finasteride | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Indomethacin | Indomethacin | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Otezla | Apremilast | 12 | suppressed |
| Permethrin | Permethrin | 12 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Fycompa | Perampanel | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
| Victoza 3-Pak | Liraglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,273.46 · 131 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Auvelity, BREZTRI, CAPLYTA, Cologuard Collection Kit, DEXCOM G7 GSS (161), DEXCOM STELO GLUCOSE BIOSENSOR, Dexcom G6 Transmitter, ELIQUIS, FANAPT, FARXIGA, Flexitouch Plus, JARDIANCE, KISUNLA, Kerendia, Korlym, MOUNJARO, Nimbl, OTEZLA, Ozempic, RECORLEV, REPATHA, REXULTI, TRELEGY ELLIPTA, TRINTELLIX, The Cologuard Plus Collection Kit, VERQUVO, VRAYLAR, Wegovy, YUPELRI, ZEPBOUND, iLet Bionic Pancreas, iLet Insulin Infusion Kit Contact Detach, iLet Insulin Infusion Kit Inset, t:slim X2 Insulin Pump with Control-IQ | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error